New Once-Daily drug may better protect transplanted kidneys
Disease control
Recruiting now
This study compares a once-daily anti-rejection drug (Envarsus XR) to a twice-daily drug (tacrolimus) in 78 adults receiving a first kidney transplant. The goal is to see if Envarsus XR reduces hidden rejection and improves immune system markers in the blood. Participants will be…
Phase: PHASE2, PHASE3 • Sponsor: Roberto Gedaly • Aim: Disease control
Last updated May 11, 2026 20:48 UTC